“The book is well presented and the price is reasonable for anyone (drug designers, medicinal chemists, biochemists, biologists, clinicians and toxicologists) interested in any of the many facets that come together to make polypharmacology.” (British Toxicology Society, 1 July 2013)
“However, anyone interested in the complex issues relating to drug promiscuity should find this very timely and topical book to be a reliable and stimulating reference that they will revisit many times.” (ChemMedChem, 2012)
“Only recently, the characterization of promiscuous ligands turned from ‘dirty drugs’ into ‘agents being rich in pharmacology.’ … Polypharmacology in Drug Discovery covers all aspects, the good, the bad and the ugly. On the one hand, a lack of specificity (the ‘bad’) causes more or less serious side effects; inhibition of certain antitargets (the ‘ugly’), e.g. the hERG channel, results in a termination of a development project, in the past even the withdrawal of already marketed drugs; on the other hand, a desired promiscuity (the ‘good’) may be beneficial, e.g. in the case of certain CNS drugs and of anti-tumor kinase inhibitors. In Peters‘ book, all these topics are discussed in great detail by internationally leading authors. Therefore, Polypharmacology in Drug Discovery is of utmost importance for all drug designers, medicinal chemists as well as biochemists and biologists. The price of the book is in excellent relationship to its 500 pages and the overall quality, in content and presentation.”―Prof. Dr. Hugo Kubinyi
From the Inside Flap
An essential outline of the main facets of polypharmacology in drug discovery research
Extending drug discovery opportunities beyond the “one drug, one target” philosophy, a polypharmacological approach to the treatment of complex diseases is emerging as a hot topic in both industry and academic research. Polypharmacology in Drug Discovery presents an overview of the various facets of polypharmacology and how it can be applied as an innovative concept for developing medicines for treating bacterial infections, epilepsy, cancer, psychiatric disorders, and more. Filled with a collection of instructive case studies that reinforce the material and illuminate the subject, this practical guide:
-
Covers the two-sided nature of polypharmacologyits contribution to adverse drug reactions and its benefit in certain therapeutic drug classes
-
Addresses the important topic of polypharmacology in drug discovery, a subject that has not been thoroughly covered outside of scattered journal articles
-
Overviews state-of-the-art approaches and developments to help readers understand concepts and issues related to polypharmacology
-
Fosters interdisciplinary drug discovery research by embracing computational, synthetic, in vitro and in vivo pharmacological and clinical aspects of polypharmacology
A clear road map for helping readers successfully navigate around the problems involved with promiscuous ligands and targets, Polypharmacology in Drug Discovery provides real examples, in-depth explanations and discussions, and detailed reviews and opinions to spark inspiration for new drug discovery projects.
From the Back Cover
An essential outline of the main facets of polypharmacology in drug discovery research
Extending drug discovery opportunities beyond the “one drug, one target” philosophy, a polypharmacological approach to the treatment of complex diseases is emerging as a hot topic in both industry and academic research. Polypharmacology in Drug Discovery presents an overview of the various facets of polypharmacology and how it can be applied as an innovative concept for developing medicines for treating bacterial infections, epilepsy, cancer, psychiatric disorders, and more. Filled with a collection of instructive case studies that reinforce the material and illuminate the subject, this practical guide:
-
Covers the two-sided nature of polypharmacology its contribution to adverse drug reactions and its benefit in certain therapeutic drug classes
-
Addresses the important topic of polypharmacology in drug discovery, a subject that has not been thoroughly covered outside of scattered journal articles
-
Overviews state-of-the-art approaches and developments to help readers understand concepts and issues related to polypharmacology
-
Fosters interdisciplinary drug discovery research by embracing computational, synthetic, in vitro and in vivo pharmacological and clinical aspects of polypharmacology
A clear road map for helping readers successfully navigate around the problems involved with promiscuous ligands and targets, Polypharmacology in Drug Discovery provides real examples, in-depth explanations and discussions, and detailed reviews and opinions to spark inspiration for new drug discovery projects.
About the Author
Jens-Uwe Peters, PhD, works in the Medicinal Chemistry Department at F. Hoffmann-La Roche. In his ten years at Roche, he has been involved in numerous drug discovery projects, has contributed to Early Safety Profiling initiatives, and has researched opportunities for polypharmacological drug discovery. Dr. Peters is author or coauthor on twenty-six journal papers and is named on twenty-two patents.
Wow! eBook
